Disclosure of HIV status: Experiences of Patients Enrolled in an Integrated TB and HAART Pilot Programme in South Africa.
The convergence between the tuberculosis (TB) and HIV epidemics has led to studies investigating strategies for integrated HIV and TB care. We present the experiences of a cohort of 17 patients enrolled in the first integrated TB and HIV treatment pilot programme, conducted in Durban, South Africa, as a precursor to a pivotal trial to answer the question of when to start antiretroviral treatment (ART) in patients co-infected with HIV and TB. Patients' experiences with integrated TB and HIV care can provide insight about the problems or benefits of introducing HIV treatment into existing TB care in resource-constrained settings, where stigma and discrimination are often pervasive and determining factors influencing treatment uptake and coverage. Individual interviews, focus group discussions, and observations were used to understand patients' experiences with integrated TB and HIV treatment. The patients described incorporating highly active antiretroviral therapy (HAART) into their daily routine as 'easy'; however, the patients experienced difficulties with disclosing their HIV status. Non-disclosure to sexual partners may jeopardise safer-sex practices and enhance HIV transmission. Being on TB treatment created a safe space for all patients to conceal their HIV status from those to whom they did not wish to disclose. The data suggest that the context of directly observed therapy (DOT) for TB may have the added benefit of creating a safe space for introducing ART to patients who would benefit most from treatment initiation but who are not ready or prepared to disclose their HIV status to others.
Gebrekristos
Hirut T
HT
Centre for AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, [Private Bag 7, Congella 4013 Durban, South Africa].
Lurie
Mark N
MN
Mthethwa
Nkosinathi
N
Karim
Quarraisha Abdool
QA
PLoS Med. 2007 Jan;4(1):e50
17253901
AIDS. 2003 Jun 13;17(9):1383-7
12799560
AIDS. 2004 Apr 30;18(7):975-9
15096799
Am J Public Health. 2007 Oct;97(10):1775-81
17761582
Soc Sci Med. 1994 Apr;38(8):1047-53
8042052
Lancet Infect Dis. 2006 Aug;6(8):483-95
16870527
Lancet. 2006 Nov 4;368(9547):1575-80
17084757
AIDS Care. 2001 Oct;13(5):595-603
11571006
Lancet. 2006 Mar 18;367(9514):926-37
16546541
Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):416-9
9373637
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):929-34
15220699
Lancet. 2001 Aug 4;358(9279):410-4
11502341
AIDS. 1991;5 Suppl 1:S127-33
1669909
AIDS. 2004 Apr 9;18(6):887-95
15060436
AIDS Patient Care STDS. 2008 Jul;22(7):587-94
18601582
Soc Sci Med. 2003 Jul;57(1):13-24
12753813
J Infect Dis. 2007 Dec 1;196 Suppl 3:S482-90
18181698
Lancet. 2006 Apr 22;367(9519):1335-42
16631912
AIDS. 2004 Jun;18 Suppl 3:S21-5
15322480
N Engl J Med. 2006 Feb 2;354(5):440-2
16452554
AIDS. 2001 Sep 28;15(14):1865-74
11579250
JAMA. 1992 Sep 23-30;268(12):1581-7
1518113
AIDS Care. 2007 Apr;19(4):572-7
17453600
Am J Public Health. 2005 May;95(5):808-15
15855456
Lancet. 2006 Jun 3;367(9525):1870-2
16753490
Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S421-8
15156433
J Infect Dis. 2007 Aug 15;196 Suppl 1:S46-51
17624825
AIDS. 2001 May 25;15(8):1045-52
11399987